Advanced Filters
noise

Carcinoma Clinical Trials

A listing of Carcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 6,070 clinical trials
T Tao Li

Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection

This is a single-center, single-arm, open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib as adjuvant therapy in hepatocellular carcinoma (HCC) patients who are at high risk of recurrence after curative resection.

18 years of age All Phase 2
J Jiangdong Sui, Ph.D, M. D.

Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

This is a multicenter, prospective, single-arm, phase II clinical study, to evaluate the therapeutic efficacy and safety of envafolimab combined with chemoradiotherapy and recombinant human endostatin in patients with locally advanced nasopharyngeal carcinoma.

18 - 65 years of age All Phase 2
M Ming-Yuan Chen

Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer

In order to further verify the effectiveness of the new prevention irradiation model for low-risk areas for nasopharyngeal carcinoma under immunotherapy, our team intends to conduct a non-inferiority clinical trial. The aim is to evaluate the efficacy and safety of two treatment modalities - local region reduced-target radiotherapy versus full-target …

18 - 70 years of age All Phase 3
S S.F. Oosting, MD, PhD

SSTR2 Imaging With [68Ga]Ga-DOTA-TOC PET/CT in NPC

This is an investigator-initiated, single-center clinical trial designed to evaluate the feasibility of [68Ga]Ga-DOTA-TOC positron emission tomography (PET) scan in patients with Epstein-Barr virus (EBV) related nasopharyngeal carcinome (NPC) prior to and three weeks after the start of induction chemotherapy or concurrent chemoradiotherapy (CRT). Archival tumor tissue from the diagnostic …

18 years of age All Phase 1/2
Q Qian Yee Chai, BSc

ChemoRT With and Without Dental Stent for Taste Protection in NPC Patients

Primary objective: Evaluate and compare incidence of acute and long-term taste dysfunction in chemoradiation plus dental stent group vs. chemoradiation group, using objective-measured taste strip test, and patient-reported taste ability and toxicity. Secondary objectives: Evaluate and compare incidence of acute and long-term toxicities (excluding taste) and patient-reported quality of life …

21 - 100 years of age All Phase 2
S Shivendra Singh, Mch

Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB)

to study role of chemotherapy treatment for gall bladder cancer before surgery as compared to surgery directly

18 - 70 years of age All Phase 3
S Shanzhi Gu, MD

A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy

The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Failed or Intolerance to Standard Therapy

18 - 75 years of age All Phase 2
S Sangang Wu, M.D.

Adebrelimab and Chemoradiotherapy in High-risk LANPC

This trial aims to study the role of Adebrelimab combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) for high-risk locoregionally advanced nasopharyngeal carcinoma(LANPC).

18 - 65 years of age All Phase 2
B Bo You

Pretreatment With HCQ Before Radiotherapy and Chemotherapy in Advanced NPC Patients

Dormant cancer cells that survive anti-cancer therapy can lead to cancer recurrence and disseminated metastases that prove fatal in most cases. Recently, specific dormant polyploid giant cancer cells (PGCC) have drawn the investigators' attention because of their association with the clinical risk of nasopharyngeal carcinoma (NPC) recurrence, as demonstrated by …

20 - 70 years of age All Phase N/A

HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of HRYZ-T102 TCR-T Cell in patients with AFP positive advanced hepatocellular carcinoma and other solid tumors refractory to prior systematic treatments.

18 - 75 years of age All Phase 1

Simplify language using AI